NCT04717908 (TB-TRUSTplus) is a NA clinical trial of Bedaquiline in Multidrug Resistant Tuberculosis, sponsored by Huashan Hospital.

Who is sponsoring NCT04717908?

NCT04717908 is sponsored by Huashan Hospital.

What drugs are being tested in NCT04717908?

Interventions in NCT04717908: Bedaquiline, Pyrazinamide, Linezolid, Cycloserine, Clofazimine.

What condition does NCT04717908 study?

NCT04717908 studies Multidrug Resistant Tuberculosis.

Is NCT04717908 still recruiting?

NCT04717908 is currently completed. Last updated 12 November 2024.

Last reviewed 2024-11-12 · How we verify

NCT04717908: TB-TRUSTplus

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS

Completed NA Last updated 12 November 2024

What this trial tests

NA trial testing Bedaquiline in Multidrug Resistant Tuberculosis in 89 participants. Completed in 22 June 2024.

Timeline

20 January 2021

Primary endpoint
22 June 2024

22 June 2024

Quick facts

Lead sponsor	Huashan Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	89
Start date	20 January 2021
Primary completion	22 June 2024
Estimated completion	22 June 2024
Sites	15 locations across China

Drugs / interventions tested

Bedaquiline (bedaquiline) — full drug profile →
Pyrazinamide (PYRAZINAMIDE) — full drug profile →
Linezolid — full drug profile →
Cycloserine (CYCLOSERINE) — full drug profile →
Clofazimine (clofazimine) — full drug profile →

Conditions studied

Multidrug Resistant Tuberculosis — all drugs for Multidrug Resistant Tuberculosis →

Sponsor

Huashan Hospital

Who can join

Adults 18 to 70, any sex, with Multidrug Resistant Tuberculosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the efficacy, safety and tolerability of a combination of bedaquiline, linezolid, cycloserine, clofazimine and pyrazinamide treatments guided by PZA sensitivity for 24 to 36 weeks in subjects with fluoroquinolone-resistant MDR-TB .

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Clofazimine for the treatment of tuberculosis.
Stadler JAM, Maartens G, Meintjes G, Wasserman S. · · 2023 · cited 52× · PMID 36817137 · DOI 10.3389/fphar.2023.1100488
Rapid Detection of Extensive Drug Resistance by Xpert MTB/XDR Optimizes Therapeutic Decision-Making in Rifampin-Resistant Tuberculosis Patients.
Chen X, Li R, Ge S, Li Y, et al · · 2023 · cited 11× · PMID 37249422 · DOI 10.1128/jcm.01832-22
Ability of the MeltPro MTB/PZA Assay to Detect Susceptibility to Pyrazinamide in Rifampin-Resistant Tuberculosis Patients.
Li R, Li Y, Chen X, Jia L, et al · · 2023 · cited 2× · PMID 37162355 · DOI 10.1128/spectrum.04836-22

Verify or expand the search:

Other trials of Bedaquiline

Trials testing the same drug.

NCT06192160 — Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis · Phase 2 · recruiting
NCT06081361 — Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezol · Phase 3 · active not recruiting
NCT05766267 — Short-course Regimens for the Treatment of Pulmonary Tuberculosis · Phase 2, PHASE3 · active not recruiting
NCT05824871 — A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients · Phase 3 · recruiting
NCT05382312 — Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established A · Phase 2 · completed

Other recruiting trials for Multidrug Resistant Tuberculosis

Currently open trials in the same condition.

NCT05081401 — Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tube · Phase 3 · recruiting

Other Huashan Hospital trials

Trials by the same sponsor.

NCT07469735 — Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma · NA · not yet recruiting
NCT07364487 — This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis · EARLY_PHASE1 · withdrawn
NCT07369830 — The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function · NA · recruiting
NCT07185373 — Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL · Phase 2, PHASE3 · not yet recruiting
NCT07075029 — RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged ≥50 Years in China · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04717908 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Huashan Hospital
Last refreshed: 12 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04717908.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing